Lourdes
Calvo Martínez
![Foto de Lourdes](/img/nophoto.png)
![Foto de Hospital Xeral Calde](/img/noimage_org.png)
Hospital Xeral Calde
Lugo, EspañaPublicacións en colaboración con investigadores/as de Hospital Xeral Calde (7)
2011
-
A dose-dense schedule of docetaxel followed by doxorubicin and cyclophosphamide as neoadjuvant treatment for breast cancer: Results from a phase II study
Clinical and Translational Oncology, Vol. 13, Núm. 9, pp. 686-691
2010
-
Adjuvant docetaxel for high-risk, node-negative breast cancer
New England Journal of Medicine, Vol. 363, Núm. 23, pp. 2200-2210
2008
-
Phase II study of dose-dense doxorubicin and docetaxel as neoadjuvant chemotherapy with G-CSF support in patients with large or locally advanced breast cancer
Clinical and Translational Oncology, Vol. 10, Núm. 11, pp. 739-744
-
Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel for early breast cancer
Journal of the National Cancer Institute, Vol. 100, Núm. 11, pp. 805-814
2007
2006
-
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): Impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen
Annals of Oncology, Vol. 17, Núm. 8, pp. 1205-1212
2005
-
Docetaxel/gemcitabine administered every other week as first-line treatment for metastatic breast cancer: Final results of a phase II trial
Clinical Breast Cancer, Vol. 6, Núm. 5, pp. 433-438